- Primary Care Is in Trouble. So Doctors Band Together To Boost Their Market Power.
- Cosmetic Surgery Investigation Prompts Warnings for Patients, and a Push for Tighter Safety Standards
- Driving the news at HIMSS26: Verily, Samsung ink collaboration; Meditech's latest AI solutions
- Minnesota to give $5M in restitution to patients of shuttered dental office
- Dental group owners, employee convicted of fraud, conspiracy
- The ‘farm mentality’ and what it means for ASCs
- What 5 physician practice closures say about the industry in 2026
- The Loss No One Measures: The True Cost of Pharmacy Vacancies
- Maryland hygiene school opens 1st VR lab
- Colorado hospitals, advocates launch youth mental health coalition
- Pennsylvania hospital CFO on life after bankruptcy: ‘You’ve got to hold the line’
- Pennsylvania hospital CFO on life after bankruptcy: ‘You’ve got to hold the line’
- Medicare allegedly paid $15M+ for ED services tied to non-ED sites: Report
- Medicare allegedly paid $15M+ for ED services tied to non-ED sites: Report
- ECMC Corp. CEO to leave for New York hospital association role
- CMS’ ambulatory specialty payment model: 10 things to know
- Climate warming could increase anxiety, depression: Study
- HSHS, Lifepoint name CEO for planned Wisconsin hospital
- Tennessee lawmakers weigh expanding optometrists’ scope of practice
- Washington hospital settles open meetings lawsuit
- ‘No rational explanation’: Hospitals warn Colorado budget cuts will shrink physician pipeline
- HCA Florida hospital CEO retires
- TriHealth CEO to retire
- Sutter Health boosts operating margin to 2.6% in 2025
- Sutter Health boosts operating margin to 2.6% in 2025
- $13.4B premium hike due to Medicare Advantage overpayments: Report
- Remarks at the Institute of International Bankers 2026 Annual Washington Conference
- Choice Healthcare Services to upgrade 2 dental practices
- The ‘perfect storm’ threatening anesthesia
- Tennessee’s CON repeal delay endangers rural health funding
- Private equity invested $1 trillion in healthcare in 10 years: Report
- Why this specialty is facing an increased risk in False Claims allegations
- Fostering Regulatory Harmony Between the SEC and CFTC
- The anesthesia reimbursement math that no longer works for ASCs
- Only 4 states satisfy over 50% of mental health workforce needs: Report
- Here's where hospital markets are the most concentrated
- Federal report scrutinizes vertical integration in dentistry: 6 notes
- A look at how CVS is leaning on 'agentic twins' in developing consumer tech
- Washington poised to ban noncompete agreements
- Elevance to expand 10% out-of-network penalty policy into California
- Bancos, primera línea de batalla contra los fraudes financieros a adultos mayores
- 1st dental MRI earns FDA clearance
- U of Minnesota requests $100M in funding to expand dental school
- Inside Grand Mental Health’s tech-enabled crisis response model
- Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses
- 14 DSO deals reshaping dentistry
- Indiana syringe services face ID requirement, restrictions
- EDs see jump in pediatric dental visits: 5 notes
- NYU Stern report calls for private equity reforms to safeguard quality of care
- AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO
- The Aspen Group’s 2025 dental growth in 10 numbers
- DME company owner sentenced in $60M fraud scheme
- Remarks at the International Bar Association’s 24th Annual International Conference on Private Investment Funds
- 2 revenue cycle leaders on strategies that reduced denials
- Raw Oysters and Clams Recalled After Norovirus-Like Illness Outbreak in Washington
- Mammograms May Also Reveal Hidden Heart Disease Risk, Study Finds
- Chile Becomes First Country in the Americas To Eliminate Leprosy
- Going Abroad? CDC Warns Travelers About Polio Risk in Several Countries
- Listen to the Latest ‘KFF Health News Minute’
- 20 payer relations executives to know
- 9 health systems naming revenue cycle vice presidents
- Más niños llegan a salas de emergencias con dolor de muelas. Los recortes de Trump y la lucha anti flúor de RFK Jr. no ayudan
- Centene's stock falls as CEO London outlines ongoing ACA headwinds
- AI-fueled misdiagnoses, rural care barriers are 2026's top patient safety threats: ECRI
- Patients want price transparency, e-commerce experience from pharma DTP platforms: survey
- Carrum Health teams up with Virta Health on a comprehensive weight loss solution
- Leerink questions whether BioNTech can thrive without their 'founders' insight' as stock drops
- Novo Nordisk's US headquarters under fire in latest FDA warning letter
- Filana leaves Cassava roots behind amid branch into epilepsy
- Nearly Half of U.S. Kids Lack Adequate Sleep, Survey Shows
- Trump Caused Immediate Decrease in Acetaminophen Rx's For Pregnant Women, Study Finds
- Students Spend A Third Of Their School Day On Their Smartphone, Study Says
- Daily Multivitamins Slow Aging, Clinical Trial Finds
- Stress of Pregnancy Complications Might Impact Future Heart Health, Study Says
- Approved IV Drug, Gazvya, Reduces Lupus Symptoms, Clinical Trial Finds
- CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago
- More Kids Are in ERs for Tooth Pain. Trump Cuts and RFK Jr.’s Anti-Fluoride Fight Aren’t Helping.
- Banks Are Becoming Bulwarks Against Scams for Vulnerable Seniors
- FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial
- BioNTech's CEO, CMO prep departure to set up next-gen mRNA company
- 12 new behavioral health sites to know
- HIMSS26: Samsung, b.well partner to 'kill the clipboard,' aligning with a key CMS goal
- HIMSS26: Epic expands AI road map, previews Factory to build and orchestrate AI agents
- A $21M farewell: Emma Walmsley lands nearly 50% pay hike in final year as GSK chief
- Fitch upgrades UCHealth’s rating to ‘AA+’
- Autism committee delays first meeting
- Maryland behavioral health providers push for 3% reimbursement rate increase
- Remarks at the 45th Annual Small Business Forum
- Founders, Funders, and Forty-Five Forums: Remarks at the 45th Annual Small Business Forum
- Remarks at the 45th Annual Small Business Forum
- Leapfrog ordered to remove safety grade for 5 Tenet hospitals
- FDA unveils 4th revision of draft guidance for looser biosimilar testing requirements
- 4 behavioral healthcare M&A deals in 2026
- 'Fibermaxxing' Trend Encourages People To Eat More Fiber
- Lilly rewards CEO David Ricks with $36.7M pay package for 2025, fueled by GLP-1 success
- Crossroads Healing Centers earns Joint Commission accreditation
- That Stressful Person in Your Life Might Be Aging You Faster, Study Finds
- Newsom se enfrenta a Trump y RFK Jr. por la salud pública
- Infant Bath Seats Sold on Amazon Recalled Due To Tipping Hazard
- FDA Vaccine Chief Dr. Vinay Prasad Exiting Role
- Spruce hooks a commercial chief to prep for rare disease launch
- Hims & Hers makes deal with Novo Nordisk as it shifts obesity strategy
- Fierce Healthcare highlights Fierce 15 of 2026 honorees at NYSE
- Universal Health Services to acquire Talkspace in $835M deal to build out virtual behavioral health
- Florida no amplió Medicaid, pero igual algunos legisladores quieren imponer requisitos de trabajo
- Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims' telehealth platform
- Sotyktu, take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis
- 'SNL' pokes fun at mysteries of Amgen's Otezla for plaque psoriasis
- Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application
- Weighted Vests Help Keep Bones Strong — But Only If Seniors Stay Active
- Small Drop In Measles Vaccinations Tied to Big Jump In Cases
- UV Air Filters Cut Airborne Asthma Triggers, Study Finds
- Many Seniors Gain Physical, Mental Fitness As They Age, Study Finds
- Common Drug Class, Anticholinergics, Shows Links to Heart Risk — Are You Taking One?
- Illicit Drugs Raise Stroke Risk, Even for Younger Adults
- Ipsen backs away from cancer med Tazverik after safety signals emerge in lymphoma trial
- Florida Hasn’t Expanded Medicaid. Lawmakers Want To Add Work Requirements Anyway.
- Omada Health swings to a profit in Q4, offers new GLP-1 cash-pay option for employers
- Most Americans Say They Don’t Trust Driverless Cars — Here’s Why
- Can The Critters in Your Mouth Cause or Cure Disease?
- FDA's Vinay Prasad to depart agency at the end of April
- KFF: A look at Part D enrollment trends for 2026
- Healthcare Dealmakers—Hims & Hers goes international with Eucalyptus purchase, Humana's CenterWell buys MaxHealth and more
- Lonza hands off capsule business to investment firm Lone Star in $3B deal
- Some Patients Keep Weight off With Fewer GLP-1 Injections, Study Finds
- Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
- Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
- RFK Jr. Urges Medical Schools To Add More Nutrition Training
- Sixth Measles Case Confirmed in New Mexico Jail
- Community Health System selling 4 Arkansas hospitals to Freeman Health System for $112M
- Philips unveils Rembra CT for acute and high-demand imaging environments
- Philips unveils Rembra CT for acute and high-demand imaging environments
- 45,000 Halo Magic Sleepsuits For Babies Recalled Over Choking Risk
- Op-Ed—American healthcare has a pricing problem
- GLP-1 Weight-Loss Drugs Prove Effective Across Diverse Patient Groups
- Angry Teens May Age Faster, Study Finds
- Chronic Pain Can Make Noise Unbearable By Rewiring The Brain, Study Says
- Telemedicine Not Closing the Mental Health Gap in Rural Areas
- Racial Disparities Persist In Lung Cancer Treatment, Study Finds
- Peanut Allergy Risk Higher If Older Sibs Eat Peanuts, Study Finds
- Salesforce partners with HealthEx, Verily and Viz.ai to build out healthcare AI agents
- Rising Tree Pollen Counts Signal Start of Allergy Season
- Experts call for more data, collaboration to address gun violence at annual Northwell forum
- Finding the Right Supportive Footwear for Pain Relief is Key, Say Podiatrists
- FTC seeing 'progress' in discussions with Optum, Caremark in insulin case
- Fewer Mothers Died During Pregnancy or After Birth in 2024
- Trader Joe's Pulls Frozen Meals Tied to 37 Million-Pound Nationwide Recall
- Optum teams with Microsoft to expand AI-powered claims platform
- RadNet Acquires Gleamer to Support Position as a Radiology Clinical AI Solutions Leader
- RadNet Acquires Gleamer to Support Position as a Radiology Clinical AI Solutions Leader
CVS Health is America’s largest drugstore chain by number of locations and second largest (after Walgreen's) by sales. It also writes health insurance policies through its Aetna subsidiary. CVS has a gigantic pharmacy benefit management (PBM) business that delivers prescription drugs for big clients like health care insurers and employers.
CVS Pharmacy will adopt a new prescription drug pricing model claimed to make prices more consistent and transparent to customers. The company will offer CVS CostVantage next year through some cash discount prescription card administrators (e.g. Good Rx). CVS Pharmacy plans to extend CVS CostVantage as CVS Caremark TrueCost to pharmacy benefit managers in 2025:
- Introduces CVS CostVantageTM and CVS Caremark TrueCostTM to drive aligned incentives and deliver a more transparent and sustainable reimbursement model
- Launches CVS HealthspireTM brand for Health Services segment that simplifies access to multi-payor capabilities, better aligns client service, and drives better outcomes and greater lifetime member value
- Demonstrates ability to unlock value across superior assets including CVS Caremark®, Aetna®, and CVS Pharmacy® businesses
- Announces quarterly dividend of sixty-six and a half cents ($0.665 cents) per share, an approximate 10% increase
- Reiterates 2023 financial guidance and initiates 2024 projections, outlining achievable long-term growth expectations with clear opportunities to outperform
WOONSOCKET, R.I., Dec. 5, 2023 /PRNewswire/ -- Today at its 2023 Investor Day, CVS Health® (NYSE: CVS) will share how its strategy and combination of assets drives reliable, diversified, and accelerating earnings growth, while also delivering superior care and value to millions of Americans.
In addition, the company will introduce a new pharmacy reimbursement model, announce a new brand for its Health Services segment, and showcase continued growth opportunities for its businesses.
"We are successfully executing on our strategy to advance the future of health care while unlocking new value for consumers," said CVS Health President and CEO Karen S. Lynch. "The combination of our businesses, and the key growth areas we have invested in, drive our ability to lower the total cost of care, improve health outcomes, and deliver on our commitments to our customers, consumers, and shareholders."
Introducing CVS CostVantage, a more transparent and sustainable model for retail pharmacy
CVS Pharmacy today announced CVS CostVantage, a new approach that evolves the traditional pharmacy reimbursement model and brings greater transparency and simplicity to the system. CVS CostVantage will define the drug cost and related reimbursement with contracted pharmacy benefit managers (PBMs) and payors, using a transparent formula built on the cost of the drug, a set markup, and a fee that reflects the care and value of pharmacy services. These changes will also help ensure that CVS Pharmacy locations will continue to be a critical touchpoint for consumers to access affordable health care in their communities.
"We are leading with an approach that will shift how our retail pharmacy is compensated by implementing a more transparent and sustainable model that fairly aligns pharmacy reimbursement to the quality services we provide," said Prem Shah, PharmD, executive vice president, Chief Pharmacy Officer and President, Pharmacy and Consumer Wellness, CVS Health. "It provides our PBM and payor clients a foundational step towards more pricing clarity for consumers."
CVS Pharmacy plans to launch CVS CostVantage with PBMs for their commercial payors in 2025, working together to ensure a smooth transition.
Following on from the launch of its Choice Formulary program earlier this year, CVS Caremark today introduces TrueCost, a model innovation that offers client pricing reflecting the true net cost of prescription drugs, with visibility into administrative fees. Simplified pricing will help consumers be confident that their pharmacy benefit is providing the best possible price and will allow members to have stable access to our national pharmacy network. Through this approach, clients will have the flexibility to choose a pharmacy benefit model that works best for the unique needs of their members and plan, and CVS Caremark TrueCost provides another valuable option for them. CVS Caremark plans to launch CVS Caremark TrueCost in 2025.
Launching CVS Healthspire to define Health Services segment
To help demonstrate the connection and convenience CVS Health uniquely delivers, CVS Healthspire will be the new branded name for the company's Health Services segment, including Caremark, CordavisTM, Oak Street Health®, Signify Health®, and MinuteClinic®. The groups within CVS Healthspire will continue to focus on integration across the company's assets to deliver connected patient care, pharmacy benefits, and innovative provider support solutions in communities across the country, making expert care simple, more accessible, and more affordable.
The CVS Healthspire brand will begin to roll out publicly this month and advance throughout 2024. Consumers will initially see "Part of CVS Healthspire" appear on select CVS Health care delivery offerings across digital and physical assets as the company continues to create an integrated ecosystem for patients.
"Delivering care in a more integrated way - especially for complex patients with chronic health conditions - improves health outcomes and the patient experience," said Mike Pykosz, CEO of Oak Street Health and interim president of Health Care Delivery. "We are already seeing the benefits of our value-based model to lower the total cost of care for customers, clients, and patients, and we believe we will build on these results as we more fully integrate with our core businesses."
Accelerating momentum through combined strength and innovation of leading businesses
While CVS Health's business segments continue to be successful and profitable on their own, there is a sizable opportunity to continue strengthening these connections and create incremental value for the overall company.
A notable example was the recent improvement of Aetna's Medicare Advantage Star Ratings. In just a year, by leveraging the power of the company's cross-enterprise assets and executional excellence, Aetna was able to achieve 87% of their members in four star plans or better for the 2025 plan year, a recovery from 21% in the previous year.
"This achievement was due to the work across our Aetna, CVS Pharmacy, and CVS Caremark colleagues. Even more important than our ratings, these teams worked together to help members improve medication adherence and overcome barriers such as costs and transportation," said Lynch. "Our strong performance in this area shows how we can quickly unite our businesses to achieve important common goals."
Reiterating 2023 financial guidance, announcing 2024 full-year projections
CVS Health interim CFO Tom Cowhey will detail the company's 2024 financial outlook, capital deployment strategy, and long-term outlook and growth targets. The company's unique combination of assets provides CVS Health with clear opportunities for long-term outperformance, including through Medicare Advantage margin recovery, incorporating Star Ratings, starting in 2025; CVS CostVantage, the company's new retail pharmacy pricing model; increased patient enrollment in Oak Street Health; expanded product offerings through Signify Health; and enhanced growth in core businesses from new offerings in health care delivery.
"By broadening our portfolio of integrated products and services, we expect to create a path to sustainable, profitable growth," Cowhey said. "Our powerful cash generation capabilities will support our strategic goals, prudent capital deployment, and attractive return profile – while also providing opportunities for meaningful long-term outperformance."
2023 Guidance
Today, the company is reiterating its 2023 guidance as shared on its November 1, 2023 earnings call:
- Total revenues: $351.5 to $357.3 billion
- Operating income: $13.6 to $14.0 billion
- Adjusted operating income: $17.2 to $17.6 billion
- GAAP diluted earnings per share ("EPS"): $6.37 to $6.61
- Adjusted EPS: $8.50 to $8.70
- Cash flow from operations: Upper-end of $12.5 to $13.5 billion
2024 Guidance
The company is initiating its 2024 full-year projections:
- Total revenues: At least $366.0 billion
- Operating income: At least $15.0 billion
- Adjusted operating income: At least $17.2 billion
- GAAP diluted EPS: At least $7.26
- Adjusted EPS: At least $8.50
- Cash flow from operations: At least $12.5 billion
Announcement of increased quarterly dividend
CVS Health has announced that its board of directors has approved a quarterly dividend of sixty-six and a half cents ($0.665 cents) per share, an approximate 10% increase from sixty and a half cents ($0.605 cents) per share. The dividend is payable on February 1, 2024, to holders of record on January 22, 2023.
About CVS Health
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Cautionary Statement Concerning Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health. Statements in this press release that are forward-looking include, but are not limited to, references to CVS Health Corporation's priority areas for strategic growth, financial outlook, long-term growth targets, capital deployment, Ms. Lynch's quotations, Mr. Cowhey's quotation, Mr. Shah's quotation, Mr. Pykosz's quotation, the information under the headings "Reiterating 2023 financial guidance, announcing 2024 full-year projections", including "2023 Guidance" and 2024 Guidance", "Introducing CVS CostVantage, a more transparent and sustainable model for retail pharmacy", "Launching CVS Healthspire Services to define Health Services segment", "Accelerating momentum through combined strength and innovation of leading businesses" and the information included in the endnotes and reconciliations. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties as described in our Securities and Exchange Commission ("SEC") filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023, June 30, 2023, and September 30, 2023 and our Current Reports on Form 8-K.
You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures, including adjusted operating income and adjusted earnings per share. In accordance with SEC regulations, you can find the definitions of the non-GAAP items mentioned, as well as the reconciliations to the most directly comparable GAAP measures, below in this press release.
Business Insider attributes the new CVS Health prescription drug pricing model to competition from Mark Cuban's much smaller Cost Plus Drugs Company operation:
https://www.businessinsider.com/cvs-pharmacy-prescription-drug-prices-mark-cuban-2023-12
How Mark Cuban forced the biggest US pharmacy to upend its business
- CVS just announced it's changing how prescription drugs get priced at its pharmacies.
- The new program includes a set markup for medication costs, a step toward drug pricing transparency.
- The retailer has been facing pressure from new models like Mark Cuban Cost Plus Drugs.
CVS just announced plans for a major shift to how drugs are sold in its pharmacies — and it's a sign the retailer is bending to market pressures.
The retail pharmacy chain is set to launch a program that will flip how its pharmacies get reimbursed by pharmacy-benefit managers and insurers. Under that program, called CostVantage, CVS's pharmacies will get paid based on the cost of the drug plus a set markup and a service fee. It's not clear if it will always lead to lower costs for customers at the pharmacy counter.
The new program offers a far simpler model than how CVS's pharmacies have traditionally been reimbursed. At least in part, it's a response to models like billionaire Mark Cuban's online pharmacy taking hold in the market.
CVS has been facing increased pressure to provide transparent drug pricing in the past two years as consumers turn to companies like Mark Cuban Cost Plus Drugs for lower drug prices. Blue Shield of California, for example, said it's ditching a CVS unit and replacing it with Cuban's company for some prescription-drug tasks. Cuban declined to comment for this story.
The billionaire's drug-pricing model, which made waves across healthcare when the company launched at the start of 2022, looks remarkably similar to the program CVS is now adopting.
Federal lawmakers and the US Federal Trade Commission have also been scrutinizing the prescription-drug supply chain. They've been especially focused on pharmacy-benefit managers and the lack of transparency around how much drugs cost.
CVS's new model "provides our PBM and payor clients a foundational step towards more pricing clarity for consumers," said Prem Shah, executive vice president, chief pharmacy officer and president of pharmacy and consumer wellness at CVS Health, in a statement.
How Mark Cuban changed drug pricing
Cuban's pharmacy buys drugs directly from manufacturers and sells them to consumers at a 15% markup, plus pharmacy fees.
The company's patients pay for the drugs out of pocket, skirting middlemen like PBMs or insurers, and generally paying far less for their medications as a result. Cost Plus says it has more than 2 million members.
Cost Plus isn't the first company to try to revolutionize how consumers pay for pricey drugs. GoodRx has offered coupons for drug discounts for more than a decade.
Still, GoodRx works with PBMs to get those discounts rather than with the pharmacies, and has made some enemies in the process. The drug-discount startup took a revenue hit last year when an unnamed grocer, rumored to be Kroger, renegotiated a number of its drug pricing contracts at once and forced GoodRx to stop offering discounts for those drugs at the grocer.
Kroger announced in July that it's now partnering with Cost Plus.
GoodRx's stock tumbled more than 6% on Tuesday, while CVS gained 3.8%.
Other healthcare firms have been feeling the pressure to provide lower prices, too. Walgreens announced a new drug-discount app last week that helps patients find savings for their prescriptions. Cigna's pharmacy-benefits unit, Express Scripts, announced a transparent pricing option last month.
CVS is the biggest US pharmacy chain by prescription revenue, followed by Walgreens, according to Drug Channels.
It's not clear if CVS's new program will result in lower prices overall for consumers. Some drugs will cost more under CostVantage, while others will cost less, according to the Wall Street Journal. The costs could also depend on the terms of an individual's insurance plan, and whether they choose to use it.
But the announcement looks to be a step in the right direction for drug pricing transparency.
CVS said it plans to launch the program in full through contracts with commercial payers in 2025.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













